Oscar Health's stock continued its post-earnings rally on Tuesday, climbing 7.9% to $23.73 in late trading, with volume nearing 13 million shares. The move reflects a shift in investor focus from top-line growth to the company's improving profitability and operational efficiency.
Margins Take Center Stage
The health insurer's first-quarter results showed a significant improvement in its medical loss ratio, which dropped to 70.5% from 75.4% a year earlier. This metric, which measures the portion of premiums spent on medical claims, is a key indicator of pricing discipline and claims management. Oscar attributed the improvement to disciplined pricing, seasonal claims patterns, and $68 million in favorable prior-period development related to risk adjustment.
While revenue of $4.65 billion rose 52.6% year over year, it fell short of consensus estimates. However, adjusted EBITDA exceeded forecasts, and GAAP earnings per share of $2.07 beat expectations. This earnings quality resonated with investors, who are now more focused on the company's path to sustainable profitability.
Membership Growth and Outlook
Oscar's membership base expanded to 3.17 million, up from 2.04 million a year earlier. CEO Mark Bertolini described the individual market as "resilient" during the earnings call, while CFO Richard Blackley noted that payment rates remained "modestly favorable" despite the expiration of enhanced premium tax credits. The company reiterated its goal of achieving "meaningful profitability" in 2026.
Broader Sector Strength
Oscar's gains were part of a broader rally in managed-care stocks, with Centene rising 5.2%, UnitedHealth gaining 3.1%, and Elevance Health adding 3.1%. However, Oscar's outperformance suggests investors are betting on company-specific factors, particularly its improving margin profile.
ACA Risks Remain
Despite the positive sentiment, risks tied to the Affordable Care Act exchanges persist. The expiration of enhanced subsidies has led to a reported decline in ACA enrollment of about 1.2 million people compared to last year, according to Axios. Analysts at Wakely estimate that 2026 enrollment could end 17% to 26% below last year's levels. Additionally, a shift toward cheaper Bronze plans may signal pressure on household budgets.
Prediction markets on Polymarket reflect ongoing uncertainty, with an 87% probability assigned to the scenario where enhanced subsidies are not extended under a Democratic-controlled House. For Oscar, this represents a policy overhang that could affect future enrollment and premium dynamics.
Outlook and Key Tests
While Tuesday's rally is supported by improved fundamentals, analysts caution that sustainability depends on maintaining claims discipline throughout the year. If medical costs rise in later quarters, or if risk-adjustment payments swing unfavorably, the current valuation could become harder to justify. For now, the market is rewarding Oscar for demonstrating that its earnings power is more tangible than previously assumed.
